Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma

Jenai Wilmoth

Kathleen Colson

Franck Dubin

Christine Kellam

isatuximab, multiple myeloma, relapsed/refractory, monoclonal antibody, CD38
CJON 2021, 25(6), 706-712. DOI: 10.1188/21.CJON.706-712

Background: Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed/refractory multiple myeloma who have received at least two prior therapies. Because isatuximab is a relatively new treatment option, published guidelines for oncology nurses are limited.

Objectives: This article provides nurses with guidance on all aspects of isatuximab administration and patient management to better support those receiving this treatment.

Methods: Data from the ICARIA-MM (NCT02990338) clinical trial and additional nursing resources were collected and condensed into concise treatment and management recommendations for the care of patients with multiple myeloma undergoing treatment with isatuximab.

Findings: Nursing care of patients prescribed isatuximab includes monitoring of clinical and laboratory parameters and requires knowledge and management of associated adverse events, including infusion reactions and neutropenia. This information could aid oncology nurses in providing optimal, treatment-specific education to patients and caregivers.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.